The budget impact of tegaserod on a managed care organization formulary

被引：0
|
作者：
Bloom, MA
Barghout, V
Kahler, KH
Bentkover, JD
Kurth, H
Gralnek, IM
Spiegel, B
机构：
[1] Innovat Hlth Solut, Brookline, MA USA
[2] Novartis Pharmaceut Corp, E Hanover, NJ USA
[3] Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, CURE Digest Dis Res Ctr, David Geffen Sch Med, Los Angeles, CA USA
[4] VA Greater Los Angeles Healthcare Syst, Dept Gastroenterol & Hepatol, Los Angeles, CA USA
来源：
VALUE IN HEALTH | 2005年 / 8卷 / 03期
关键词：
D O I：
10.1016/S1098-3015(10)62991-9
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：370 / 370
页数：1
相关论文
共 50 条
  • [1] Budget impact of tegaserod on a managed care organization formulary
    Bloom, MA
    Barghout, V
    Kahler, KH
    Bentkover, J
    Kurth, H
    Gralnek, IM
    Spiegel, BMR
    AMERICAN JOURNAL OF MANAGED CARE, 2005, 11 (01): : S27 - S34
  • [2] MANAGED CARE ORGANIZATION - LIMITED DRUG FORMULARY
    KLAPPER, JA
    HEADACHE, 1994, 34 (06): : 378 - 378
  • [3] BUDGET IMPACT OF LORCASERIN FOR THE TREATMENT OF OBESITY IN A MANAGED CARE ORGANIZATION
    Knoth, R. L.
    Nikonova, E.
    Wang, Z.
    VALUE IN HEALTH, 2017, 20 (05) : A215 - A215
  • [4] MANAGED CARE ORGANIZATION BUDGET IMPACT OF ADDING RECOMBINANT FACTOR VI FC FUSION PROTEIN (RFVIIIFC) TO THE FORMULARY FOR THE TREATMENT OF HEMOPHILIA A
    Buckley, B. C.
    Livingston, T. P.
    Eldar-Lissai, A.
    Hall, E. C.
    VALUE IN HEALTH, 2015, 18 (03) : A294 - A294
  • [5] HEADACHE FORMULARY FOR MANAGED CARE ORGANIZATIONS
    VONSEGGERN, R
    HEADACHE, 1995, 35 (01): : 52 - 53
  • [6] Appropriate prescribing of tegaserod - A look at a managed care population
    Margolis, J
    Tan, J
    Wertz, D
    Dastani, HB
    Kahler, KH
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2005, 100 (09): : S345 - S345
  • [7] Cost of access by formulary type: A case study of sildenafil citrate in a large managed care organization
    Benson, S
    Duttagupta, S
    Poller, L
    VALUE IN HEALTH, 2003, 6 (03) : 379 - 379
  • [8] The managed care approach to placing a drug on formulary
    Bronson, DM
    CUTIS, 2004, 73 (05): : 33 - 33
  • [9] Budget impact of adding doripenem to a hospital formulary
    Kongnakorn, T.
    Merchant, S.
    Akhras, K.
    Ingham, M.
    Mody, S.
    Mwamburi, M.
    Caro, J. J.
    VALUE IN HEALTH, 2008, 11 (03) : A94 - A94
  • [10] Characterization of tegaserod-treated patients in a managed care population
    Stephenson, JJ
    Fernandes, J
    Kahler, KH
    Barghout, V
    Boccuzzi, SJ
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2004, 99 (10): : S238 - S238
12345